Abstract
Atrial fibrillation (AF) is largely co-morbid with heart failure (HF), worsening prognosis in patients with ventricular dysfunction. Treating AF through ablation can improve outcomes and reduce the transition to end-stage HF, highlighting the importance of early recognition in patients with ventricular dysfunction. Circulating NT-proBNP is a well-known biomarker for AF in patients with ventricular dysfunction, however, large individual variability limits its predictive power and therefore utility. With the rise of high-throughput proteomics in the era of precision medicine, novel and stable biomarkers may be identified with the potential to improve risk stratification, detection, and management.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call